It Establishes New Marks
DNMT3B is primarily associated with de novo methylation—the establishment of DNA methylation at locations that were not already carrying the same mark.
Learn how DNA methyltransferase 3 beta helps establish new DNA methylation patterns, how this differs from folate and methyl-donor metabolism, and why one DNMT3B variant cannot diagnose an epigenetic or medical condition.
DNMT3B provides instructions for an enzyme that adds methyl groups to selected cytosine bases in DNA. It is mainly associated with establishing new, or de novo, DNA methylation patterns rather than simply copying an existing pattern.
DNA methylation is an epigenetic modification. In this process, a methyl group is attached to DNA—commonly to cytosine within a CpG site—without changing the underlying sequence of DNA letters.
DNMT3B is one of the enzymes capable of adding these marks. It is especially associated with establishing new DNA methylation patterns during development and in specific genomic regions.
These marks can be connected with chromosome organization and regulation of gene activity, but DNA methylation is not a universal on-or-off switch. The effect depends on the location, cell type, developmental stage and wider biological context.
Before interpreting a highlighted result, review SNPs and methylation and genetic variants versus mutations.
DNMT3B connects methyl-donor chemistry with the placement of methyl marks on DNA, but its role must be distinguished from broader nutritional and wellness claims.
DNMT3B is primarily associated with de novo methylation—the establishment of DNA methylation at locations that were not already carrying the same mark.
The enzyme uses S-adenosylmethionine, or SAM, as the source of the methyl group transferred to cytosine in DNA.
DNA methylation patterns participate in development, chromosome organization, genomic imprinting and context-dependent regulation of gene activity.
This simplified sequence explains the enzyme reaction without suggesting that DNMT3B acts on every cytosine or controls every epigenetic mark.
S-adenosylmethionine supplies the methyl group for the reaction.
DNMT3B interacts with selected DNA regions and cytosine bases.
DNMT3B transfers the methyl group onto the cytosine base.
The DNA sequence remains the same, but an epigenetic mark has been added.
DNA methylation patterns involve several enzymes and regulatory proteins. Consumer reports should not describe one DNMT3B variant as the complete control point.
DNMT3A is another DNA methyltransferase associated with establishing new methylation patterns. Its targets and biological roles overlap with, but are not identical to, DNMT3B.
DNMT3B contributes to de novo methylation, including methylation in specific repetitive and developmentally important genomic regions.
DNMT1 is mainly associated with copying existing DNA methylation patterns after DNA replication so the pattern can be maintained in daughter cells.
The enzymes can cooperate, and their activity depends on interacting proteins, genomic location, cell type and developmental timing.
Both involve methyl groups, but they answer different biological and testing questions.
DNMT3B transfers methyl groups onto DNA. This creates epigenetic marks associated with genome organization, development and context-dependent gene regulation.
A DNMT3B genetic test identifies inherited variants in the DNMT3B gene. It does not directly map your present DNA methylation pattern.
Folate, vitamin B12, choline and methionine-related pathways help produce and recycle compounds used to make SAM, the methyl donor used by many enzymes.
These pathways help supply methyl groups, while DNMT3B is one enzyme that places a methyl group onto DNA.
Responsible interpretation separates an inherited DNA variant from current enzyme activity, epigenetic patterns and health outcomes.
Rare pathogenic variants affecting both copies of DNMT3B can cause immunodeficiency-centromeric instability-facial anomalies syndrome type 1, commonly shortened to ICF1 syndrome.
ICF1 is a rare inherited disorder involving characteristic clinical and laboratory findings. It is different from receiving a common DNMT3B SNP in an educational wellness report.
A consumer test does not diagnose ICF syndrome. A concerning result, relevant symptoms or family history requires evaluation through an appropriately qualified genetics or healthcare professional and, when indicated, clinical diagnostic testing.
Not every methylation panel includes DNMT3B, and two US testing providers may examine different variants or return very different explanations.
Before ordering, check what is actually tested, what the report claims and whether the provider clearly distinguishes wellness education from clinical genetic testing.
A test advertised as a methylation or MTHFR panel may not include DNMT3B. Review the complete published gene list.
Look for an rsID, genomic notation or other precise variant identifier instead of a general “DNMT3B positive” label.
A wellness report is different from clinical sequencing intended to investigate a suspected inherited disorder.
Check which laboratory processes the sample, the testing method and any quality or validation information provided.
Rural residents may need additional time for kit delivery, sample return and laboratory receipt compared with major metro areas.
Where local genetics services are limited, ask whether qualified professional support is available locally or through an appropriate remote option.
Review how your sample, report, personal information and raw genetic data may be stored, retained, shared or deleted.
Different companies may test different variants or apply different evidence standards, even when both reports use the DNMT3B gene name.
DNMT3B places methyl marks on DNA, but it depends on methyl-donor availability and works within a larger network of DNA methyltransferases, regulatory proteins and one-carbon metabolism pathways.
A broader panel can provide context, but more genes do not automatically make a report diagnostic. Each finding still needs to be evaluated according to the exact variant and quality of evidence.
Start with genes included in a methylation test, then use how to read methylation test results before drawing conclusions.
Identify the exact DNMT3B variant, your reported genotype and the laboratory method used.
Separate established enzyme function from uncertain claims about symptoms, aging, detoxification or disease risk.
Use wellness findings for education and seek clinical evaluation when symptoms, family history or a potentially pathogenic result justify it.
A DNMT3B result cannot determine whether you need methylfolate, vitamin B12, SAMe, another supplement or a medical treatment. Do not change medication, supplements or care based only on a consumer report.
Use these resources to review gene coverage, variant terminology, report limitations and official gene information.
Clear answers about DNMT3B function, DNA methylation, common variants, ICF syndrome and at-home genetic testing.
DNMT3B is a protein-coding gene that provides instructions for DNA methyltransferase 3 beta, an enzyme that adds methyl groups to selected cytosine bases in DNA.
DNMT3B directly performs DNA methylation. It uses SAM as a methyl donor and transfers a methyl group onto cytosine in DNA.
De novo methylation means establishing a new DNA methylation mark rather than mainly copying an existing mark after DNA replication.
No. DNMT3B is mainly associated with establishing new DNA methylation patterns, while DNMT1 is mainly associated with maintaining existing patterns after DNA replication.
No. A genetic test identifies inherited variants in the DNMT3B gene. Measuring current DNA methylation patterns requires a different type of laboratory analysis.
No. One inherited DNMT3B variant cannot show which genes are currently active or inactive in your cells. Gene regulation depends on many interacting factors and varies between tissues.
No. A consumer DNMT3B result does not diagnose cancer or determine whether abnormal DNA methylation is present in a tumor or other tissue.
Rare pathogenic variants affecting both copies of DNMT3B can cause ICF syndrome type 1. This rare condition is different from receiving a common variant in an educational wellness panel.
No. A DNMT3B genotype alone cannot determine whether methylfolate, SAMe, vitamin B12 or another supplement is necessary or safe.
DNMT3B uses SAM to add methyl marks to DNA, while other genes contribute to producing methyl donors, maintaining DNA methylation and regulating chromatin and gene activity.
An at-home genetic panel may use a cheek-swab sample, but not every methylation test includes DNMT3B. Confirm the gene and exact variants before ordering.
Yes. Providers may examine different variants, use different laboratory methods or interpret the same finding using different evidence standards.
Review whether DNMT3B is included, the exact variants tested, the test's intended use, laboratory information, sample process, price, shipping, privacy terms, report limitations and support options.
A useful report should identify the precise DNMT3B finding, explain the difference between genetic and epigenetic testing, connect the gene with related pathways and clearly state what cannot be concluded.